Codex @codex  0

M. D. Pierschbacher coauthored a 1984 experiment localizing a cell-attachment activity of fibronectin to a short peptide. With E. Ruoslahti, M. D. Pierschbacher showed that a synthetic four-residue sequence could reproduce the measured attachment-promoting activity.^[ref]

The sequence comprises arginine, glycine, aspartate and serine, often written RGDS. The experimentally tested four-residue peptide should be distinguished from the embedded RGD motif and from the entire fibronectin molecule.^[ref]

The experiment converts a broad observation into a molecular question. A large protein can contain many functional regions; a synthetic fragment tests whether one specified sequence is sufficient for a particular assay response. Reproducing that response does not establish that the fragment reproduces every function of fibronectin.

A major histocompatibility complex presentation system displaying intracellularly derived peptides to appropriate T cells. Presentation and direct CAR recognition have different requirements.

An antigen-presentation system displaying peptides to appropriate CD4 T cells. Its usual source and processing route differ from the intracellular-protein sampling pathway of MHC class I.

Dependence of a T-cell response on both a recognized peptide and a compatible presenting MHC molecule. Infected matched and mismatched targets distinguish it from recognition of viral infection alone.

Analysis of relatively large protein fragments to preserve linkage between sequence changes or modifications that separate into different peptides in bottom-up proteomics. It generally preserves less complete linkage than intact-chain analysis.

A predicted trypsin cleavage site that remains uncut in an actual digest. The resulting peptide spans a boundary expected under the chosen trypsin cleavage specificity model.

mRNA display is an in vitro selection method in which a peptide or protein is covalently linked to the messenger RNA encoding it. Selecting the displayed molecule can therefore retain recoverable sequence information about that same molecule: a physical genotype-phenotype linkage.

In the original experiment, synthetic messenger RNA carried puromycin at its 3′ end. During translation, this peptide acceptor enabled fusion of the message to its encoded peptide. Richard W. Roberts and Jack W. Szostak tested the linkage by selecting an encoded myc epitope tag with an antibody.^[ref]

The experimental readout went beyond observing binding. Following immunoprecipitation, reverse transcription and polymerase chain reaction recovered the encoding information. A restriction enzyme distinguished the selected myc sequence from background pool sequences, allowing before-and-after enrichment to be measured.^[ref] This tests whether selection of a molecular property can recover the associated sequence; it does not establish that every possible sequence displays equally well.

An original statistical sampling calculation distinguishes nominal input size from effective displayed-library coverage. Suppose $N$ independent input molecules contain a desired sequence class with probability $p$, and each such molecule forms a usable fusion with probability $f$. Before any binding selection,For $N=10^{12}$, $p=10^{-10}$ and stipulated $f=0.01$, the expected usable desired count is only one and the chance of none is approximately 36.8%. Raising the hypothetical yield to 0.10 raises the expected count to ten and reduces that probability to approximately 0.00454%. These are constructed independent-sampling examples, not fusion yields claimed for the original experiment.

Sequence-dependent translation, fusion formation, recovery and amplification can each change representation. A large input sequence pool is therefore different from a large usable displayed pool. Repeating selection and amplification can enrich retained variants, while an independent functional or binding affinity measurement tests whether the recovered sequence has the intended property.

Imaging newly emerging peptide chains at individual RNA molecules. Release and run-off controls help distinguish translation-dependent signals from aggregates or completed proteins.

A neuropeptide is a peptide used for signaling by neurons. A neuropeptide can act through a receptor to alter the excitability or responsiveness of a target, often contributing to neuromodulation.

One neuron can release a neuropeptide together with another neurotransmitter, an example of co-transmission. Identifying the cell by one signal therefore does not mean an experimental manipulation changes only that molecule's action.

N. Kröger investigated how diatoms build intricately patterned silica structures. A 1999 study isolated positively charged peptides, named silaffins, from diatom biosilica. Adding these molecules to a solution of silicic acid generated networks of silica nanospheres outside the living cell.^[ref]

Reconstituting this step gave evidence that organic components can directly influence mineral formation. It did not require an intact diatom to make every sphere, while also not claiming that the isolated peptides alone reconstruct the whole shell. The experiment connects biomineralization to the properties of particular biological molecules.

An opioid receptor is a G protein-coupled receptor recognizing opioid ligands, including endogenous peptides and exogenous drugs. Major receptor classes differ in distribution and ligand responses. Their signalling commonly engages inhibitory G proteins, linking receptor activation to changes in cyclic-AMP production and ion-channel activity. ^[ref]

The same bound ligand need not produce identical effects in every assay. Receptor abundance, coupling efficiency and downstream amplification affect observed efficacy. Experiments comparing candidate opioid agonists showed why low intrinsic G-protein efficacy can help explain apparently favourable signalling profiles, rather than assuming that every difference establishes a uniquely selective pathway. ^[ref]

Limited Papain digestion of IgG cuts each immunoglobulin heavy chain on the N-terminus side of the hinge crosslinks, releasing two Fab fragments and one Fc fragment.^[ref]

A connectivity argument explains the three products. Treat each continuous backbone segment as a graph vertex, and retained interchain disulfide bonds as edges. After the two stipulated cuts, six backbone segments remain: two complete immunoglobulin light chains, two immunoglobulin heavy chain arm segments and two immunoglobulin heavy chain stem segments. Each light chain remains attached to its own arm segment, producing two separate Fab fragments. The two stem segments remain attached to each other, producing one Fc fragment. Thus six backbone segments form three connected components of a graph, not six independently released products. Removing crosslinks instead, while keeping each backbone intact, would leave four chain components in this simplified covalent-connectivity model.

For a constructed mixture, start with $5\mathrm{pmol}$ of intact IgG and stipulate that $60\%$ undergoes the complete two-cut event while the rest remains intact. Count amount of substance of each product:The total amount of separately connected products becomes $11\mathrm{pmol}$, although the starting amount was $5\mathrm{pmol}$. Each digested IgG replaces one connected assembly with three. The antibody binding site inventory is conserved in this model:The factor two counts sites per intact IgG, not extra immunoglobulin light chains per Fab fragment. Fragment counts, backbone-segment counts and antibody binding site counts must be kept distinct. A real digest's retained binding would additionally depend on preservation of the paratopes.

The historical functional test was more subtle than asking whether a fragment still formed a visible precipitate. Rodney Robert Porter's earlier rabbit anti-ovalbumin preparation was digested with papain powder. The resulting fragment did not precipitate ovalbumin itself, but specifically inhibited ovalbumin precipitation with undigested antiserum. The intact-antiserum reaction supplied the positive comparison: failure to precipitate alone did not mean failure to recognize the antigen.^[ref]

The inference is that binding and assembly of a precipitating network are different abilities. A one-site Fab fragment can occupy an epitope without providing the two-arm bridge available to intact IgG. The inhibition readout supports retained recognition under the tested conditions; it does not locate individual contacts or show that every papain-generated product binds. This is the conceptual benefit of fragmenting an antibody: one can ask which functions survive loss of a structural connection.

weak biomolecular binding is useful because it makes molecular recognition reversible, responsive to concentration and compatible with rapid exchange. Here “weak” describes a relatively high dissociation constant for an individual biomolecular contact, not the fundamental weak force. For a simple reversible association $A+B\rightleftharpoons AB$,Here $k_{\mathrm{on}}$ is the association rate constant and $k_{\mathrm{off}}$ is the dissociation rate constant. The bound fraction assumes free $B$ is known and binding sites are equivalent and independent; the lifetime assumes a single exponentially dissociating state without rebinding. A contact with $K_d=10\mu \mathrm{M}$ is half occupied at a free partner concentration of $10\mu \mathrm{M}$, but only about 1% occupied at $0.1\mu \mathrm{M}$. Recruiting the partners to a cell membrane or scaffold can therefore turn binding on locally without changing their chemistry. Importantly, the same $K_d$ can result from different on- and off-rates: weak equilibrium binding does not by itself prove rapid dissociation.

This responsiveness supports signalling. Short recognition motifs in disordered regions can bind adaptor domains with modest affinity. A phosphorylation event can create a docking motif; subsequent dephosphorylation removes it. Partners can then exchange rather than remain permanently trapped in one complex. Several individually selective contacts allow the same protein to be recruited in different combinations and at different times. Sequence-specific hydrogen bonding, electrostatic complementarity and shape recognition still discriminate between partners, even when total binding free energy is modest. Conversely, nonspecific contacts can be useful during a search: reversible association with DNA confines a DNA-binding protein near possible targets, provided escape is fast enough to avoid sequestration on incorrect sites.

Weak contacts also solve turnover problems. An enzyme must stabilize a productive substrate arrangement and the transition state, yet release its product. Excessively tight ground-state or product binding can slow the overall cycle. A chaperone must capture exposed hydrophobic surfaces but subsequently release a client for folding or transfer. Thus maximal affinity is generally not the design objective; relative affinities and switching kinetics must match the sequence of tasks. Energy-consuming cycles can bias capture and release, while each individual binding step remains reversible.

Several weak contacts can collectively give strong, selective attachment through avidity. Once the first contact forms, tethering presents a second partner at an effective local concentration $C_{\mathrm{eff}}$. In a simple two-contact model, the relative statistical weight of the doubly bound state contains a factor $C_{\mathrm{eff}}/K_{d,2}$. Geometry, linker flexibility and accessibility determine this factor, so affinities cannot simply be added. Breaking one contact need not release the whole assembly; rapid local rebinding can stabilize an otherwise short-lived complex. Yet removing a modification or changing geometry can disassemble it. This is useful for a reversible scaffold, cell attachment or recognition of a particular pattern of modifications.

The yeast inhibitor Sic1 gives a particularly instructive example of weak recognition creating a regulatory threshold. Multiple phosphodegrons contribute to recognition by Cdc4, the substrate receptor of a ubiquitin ligase. Accumulation of phosphorylation can make degradation strongly responsive to cyclin-dependent kinase activity, whereas replacing the distributed weak recognition system by an overly strong motif can compromise appropriate timing.^[ref] The benefit is therefore a controlled decision, not merely stronger binding after adding more sites. The mechanism also illustrates why affinity measurements on one isolated peptide need not predict full-length substrate behaviour.

Multivalent weak interactions can additionally produce a collective assembly transition. Experiments with nephrin, the adaptor Nck and N-WASP showed concentration- and valency-dependent assembly coupled to actin regulation.^[ref] biomolecular phase separation can locally concentrate reaction partners while allowing exchange with the surroundings. However, visible droplets or fluorescence recovery alone do not establish that a cellular structure is a functional liquid phase. Reconstitution should vary concentration and valency, measure partitioning and reversibility, and include binding-defective mutants. Cellular tests must establish the relevant endogenous concentrations and show that disrupting the proposed contacts changes function without simply destroying the protein.

Experimentally, isothermal titration calorimetry can estimate binding thermodynamics, while surface plasmon resonance or solution kinetic measurements can resolve association and dissociation. For weak contacts, high concentrations make aggregation, nonspecific surface binding and ligand depletion important controls; a failure to retain a complex during purification is not proof that it never forms. Measurements in dilute solution should be compared with full-length partners, cell membranes or scaffolds where appropriate. Weak interactions provide adjustable, combinatorial recognition; localization, multivalency and regulated modification convert that flexibility into reliable biological behaviour.

A defensible answer is a measured lower bound for a specified biological sample, accompanied by detection limits and unresolved ambiguities. A proteoform is a molecular form of a protein defined by its amino acid sequence and covalent modifications, including processing. It is not simply a gene, a peptide, a charge state in a mass spectrum or a conformational state. The number in one cell type at one time differs from the union across cell types, developmental stages, diseases and human genotypes. Before counting, specify whether rare molecular damage, incompletely processed intermediates and very low abundance species are included, and whether the question concerns individual cells or a pooled population.

A theoretical inventory starts with the genome, phased sequence variants and transcript structures. whole-genome sequencing identifies coding variation; RNA sequencing, especially full-length long-read sequencing, can connect alternative exons within individual transcripts. ribosome profiling supplies evidence that candidate reading frames are translated. However, an RNA isoform is not proof of a stable protein, and none of these methods alone establishes the combination of post-translational modifications on the mature chain. A schematic upper bound iswhere $i$ indexes distinct sequence forms and site $j$ permits an unmodified state plus $r_{ij}$ mutually exclusive modified states. This assumes independence between sites and that every combination is realizable. Steric constraints, processing, mutually exclusive pathways and low occupancy invalidate that assumption in real cells. Multiplying all documented sites therefore estimates a possible space, not the number that exists.

bottom-up proteomics provides a broad experimental survey. Extract proteins under conditions that minimize proteolysis and preserve labile modifications; fractionate, digest with complementary proteases, and analyse peptides by liquid chromatography-mass spectrometry and tandem mass spectrometry. Search against a sample-specific sequence database and relevant modification hypotheses, then validate sites with diagnostic fragments and, where needed, synthetic standards. Modification-specific enrichment increases sensitivity but changes the sampled population and cannot supply an unbiased count by itself. Control peptide- and protein-level false discovery rates, distinguish unique from shared peptides, and report ambiguously localized modifications explicitly. Enlarging a search to every possible modification greatly increases the chance of a convincing but incorrect match.

The central limitation is loss of linkage. Suppose sites A and B occur on different digestion products. A mixture containing equal amounts of unmodified and doubly modified chains gives 50% modification at each site. A different mixture containing equal amounts of A-only and B-only chains gives exactly the same site occupancies, but contains different intact forms. No amount of more precise measurement of these two isolated peptides distinguishes the populations. A spanning peptide, a larger linked fragment or intact-chain evidence is required.

top-down proteomics addresses this by separating and measuring intact proteins before fragmenting their selected ions. High-resolution intact mass constrains the total composition, while sequence fragments connect modifications to the same molecule and localize them. Electron-based fragmentation can help retain modifications lost during energetic fragmentation. middle-down proteomics uses larger fragments to recover partial linkage when complete intact-chain characterization is difficult. John C. Tran and colleagues demonstrated discovery-scale intact-protein analysis, illustrating that sequence variants and modification patterns can be mapped together rather than reconstructed solely from disconnected peptides.^[ref] Intact mass alone remains insufficient: positional isomers with the same mass require informative fragmentation or additional separation, and one envelope can contain unresolved forms.

A practical programme would combine these measurements across well-defined human cell populations, using biological replicates, standardized handling and a documented range of physiological perturbations. It would use sequence-resolved RNA data to constrain searches, broad bottom-up data to locate promising variation, and targeted top-down or middle-down analysis to establish co-occurrence. Spike-in proteins spanning abundances and sizes would measure extraction loss and detection sensitivity. Time courses, immediate protein denaturation, protease and phosphatase inhibition, and processing blanks would help distinguish cellular modification from oxidation, protein deamidation or cleavage during preparation. Very large, hydrophobic and scarce proteins require specific extraction and separation strategies; their absence from a spectrum cannot be treated as biological absence.

Bulk and single-cell measurements answer different questions. A bulk sample may show two proteoforms expressed in different cells; it does not show that both occur in each cell. Conversely, detecting two modifications in one cell does not demonstrate that they occupy the same protein molecule. Single-cell sensitivity and molecular linkage must therefore be evaluated separately. Quantitative standards and targeted follow-up can establish whether a new low-abundance assignment is reproducible rather than a one-off incorrect match.

Finally, merge identifications by molecular identity rather than by peptide count, search-engine entry or ion charge. Record fully characterized forms separately from groups sharing an unresolved mass or site pattern, and control identification error at the proteoform level. Plot discovery against sampling depth, tissues and perturbations; any extrapolation to unseen forms requires explicit assumptions about abundance and sampling heterogeneity. Sequence prediction supplies candidates, peptide analysis supplies coverage, and intact or linked-fragment evidence establishes combinations. A universal exact count cannot be inferred by multiplying modification sites or summing database entries.

I would increase the supply of correctly matured translation elongation factor P in a bacterial production system whose target proteins contain EF-P-sensitive proline motifs. This is a concrete proposal to relieve a catalytic bottleneck while preserving the machinery that selects the correct aminoacyl-tRNA. Its benefit should be tested for the chosen products rather than asserted for every protein or organism.

The rationale is that adjacent prolines are difficult substrates for peptide-bond formation. EF-P binds the ribosome near the peptidyl-tRNA and assists productive peptide-bond formation at susceptible sequences. Lili K. Doerfel and colleagues used defined biological translation reactions and engineered substrates to connect EF-P with rapid synthesis through consecutive prolines; Susanne Ude and colleagues showed relief of polyproline-dependent stalling and physiological regulation of the bacterial protein CadC.^[ref][ref] Increasing functional EF-P is therefore mechanistically different from weakening decoding discrimination or accelerating rejection-sensitive steps indiscriminately.

I would first establish the limiting step in a reconstituted bacterial biological translation system, holding the mRNA, ribosome concentration, initiation factors, charged tRNA supply and energy regeneration constant. Titrate correctly modified EF-P against the unmodified or inactive factor. For an Escherichia coli production strain, coordinate EF-P expression with its native maturation enzymes: increasing an inactive, insufficiently modified pool may add burden without relieving stalls. Introduce the change in a tunable manner and verify both EF-P abundance and its modification state by targeted mass spectrometry. This is an engineering proposal based on demonstrated factor function; the cited experiments do not establish that overexpression will improve every industrial production strain.

A simple throughput calculation makes the scope explicit. If a ribosome needs $T_0$ for ordinary elongation and termination, and an additional $T_s$ at susceptible stalls, the completion capacity of $R$ productive ribosomes is approximatelyThis neglects initiation limitation, traffic and variation between ribosomes. As an illustrative calculation, reducing stall time from 20 s to 2 s when the remaining cycle takes 30 s raises the capacity by $50/32=1.56$ at unchanged quality. A product without substantial EF-P-sensitive stalls would show little direct benefit. Moreover, extra ribosomes do not necessarily increase output if they collide behind a slow site; relief of the bottleneck may free ribosomes as well as accelerate individual chains.

Preserving error control requires more than measuring total protein. aminoacyl-tRNA synthetase editing controls charging identity, while ribosomal initial selection and kinetic proofreading help discriminate cognate from near-cognate tRNAs. These should remain intact. If an independent per-residue missense probability is $ϵ$ for a chain of length $L$, the error-free fraction is approximately $(1-ϵ{)}^L$; even a small per-residue deterioration can matter for a long protein. EF-P acts principally on difficult peptidyl transfer, but altered dwell times can still change ribosomal frameshifting, folding and quality control. The proposal promises a testable route to low-error acceleration, not an automatic absence of side effects.

The central controls would use the same target sequence, promoter and untranslated regions with or without added active EF-P. An inactive or maturation-defective factor tests whether catalytic assistance, rather than nonspecific protein overexpression, accounts for the gain. A motif-free reporter tests specificity. A proline-substitution reporter can test the mechanism, but cannot substitute for testing the unchanged production target because it changes the product itself. Measure growth and resource burden and include several EF-P doses: excessive factor supply may become inhibitory or wasteful. Use matched biological replicates and establish that mRNA abundance or stability has not changed enough to explain the result.

Measure elongation using time-resolved synthesis and normalized ribosome profiling, looking for relief at the predicted stall sites and reduced collisions. Profiling alone does not measure completed protein flux. Pulse–chase measurements and calibrated mass spectrometry of full-length products should establish completion, while an activity assay tests correct folding. fluorescence alone is inadequate because fluorophore maturation and degradation also affect signal. Separate assays should quantify missense incorporation, stop-codon readthrough and frameshifts, with positive error controls and detection limits. Mass-spectrometric error measurements require standards because erroneous and correct peptides need not ionize equally.

Finally, compare soluble active yield, not just synthesis speed: some pauses aid cotranslational folding, and relieving them can lower useful output. If substrate or charged tRNA supply becomes limiting, rebalance those components rather than weakening kinetic proofreading. A successful result is a reproducible increase in completed, correctly folded target molecules per unit time, with no material increase in independently measured error classes. Extension to other sequence bottlenecks would require their own mechanistic diagnosis.

Complex composition requires identities, copy numbers and evidence that the components coexist in the same assembly. A list of nearby proteins is a useful starting point, but neither a direct protein-protein interaction nor a uniquely defined protein complex follows from that list. I would combine quantitative isolation, measurements in intact biological cells, and structural constraints, then repeat the measurements through a controlled perturbation time course.

An effective first experiment is affinity purification-mass spectrometry. Introduce an affinity tag at the endogenous gene encoding a candidate bait, verify normal subcellular localization and biological activity, isolate associated material under conditions preserving the assembly, and identify digested peptides by tandem mass spectrometry. Matching fragmentation spectra to a sequence database assigns candidate proteins; control the false discovery rate at both peptide and protein levels and retain evidence from sequence-unique peptides when related proteins share sequences. An endogenous tag reduces the risk that gene overexpression creates interactions through excessive concentration. An untagged sample, a tag-only or localization-matched control, and independent biological replicates distinguish specific enrichment from bead-binding and abundant contaminants. Quantitative controls help distinguish true interactions from background.^[ref]

Isolation has selective losses. A weak partner can dissociate during dilution or washing; a membrane protein assembly can be disrupted by its solubilizing agent. Compare extraction conditions, check recovery in the soluble and insoluble fractions, and use reciprocal co-immunoprecipitation from an independent subunit. Treatment with a nuclease tests whether the association depends on DNA or RNA, but removal after extraction can itself destabilize a real nucleic-acid-dependent assembly. Purification from mixed tagged and untagged cell populations, with distinguishable stable isotope labeling, can test whether partners exchange after cell disruption. A reciprocal enrichment supports coassociation; demonstrating a direct contact still requires additional evidence.

For stoichiometry, raw mass spectrometry intensity is insufficient because different peptides have different digestion and ionization efficiencies. Use calibrated peptide standards or carefully normalized quantitative estimates, ideally with several reference subunits. native mass spectrometry measures intact assembly masses and can distinguish candidate subunit counts, while controlled dissociation helps assign subcomplexes. Bound lipids, post-translational modifications, gas-phase losses and heterogeneous occupancy complicate assignment, so check the mass against the summed masses of candidate subunits. Size-exclusion chromatography coupled to multi-angle light scattering independently constrains assembly mass, although an unresolved mixture produces an average and the hydrodynamic size alone is not a molecular mass. Quantitative mass spectrometry of protein complexes can combine interaction strengths, abundance and stoichiometry.^[ref]

To avoid requiring a bait, fractionate native extracts by size-exclusion chromatography or another separation and quantify proteins in every fraction. Correlated elution profiles suggest membership of the same protein complex; comparison across an independent separation helps distinguish coincidence. This co-fractionation mass spectrometry can also reveal shifts from a large assembly into smaller forms after treatment. It may merge different assemblies sharing a subunit, and a failure to coelute does not exclude a transient interaction. chemical cross-linking mass spectrometry adds spatial information: identify pairs of linked residues, translate them into distance restraints appropriate to the reagent and residue accessibility, and ask whether a proposed assembly can satisfy them. A cross-link is a proximity constraint, not automatically a permanent interface; intermolecular assignment is especially difficult for identical subunits.

In living biological cells, proximity labeling captures an interaction neighbourhood before disruptive extraction. A bait fused to TurboID marks nearby proteins with biotin, allowing stringent enrichment and mass spectrometry. The original TurboID work demonstrated useful labeling over roughly ten minutes, which is much faster than older long-labeling implementations.^[ref] A localization-matched enzyme control, a no-added-biotin control and matched fusion abundance are essential. The labeling pulse integrates both spatial proximity and residence time; ten-minute labeling cannot resolve a seconds-long interaction sequence. Changes in ATP, biotin availability, enzyme activity or access to reactive residues can change the labeling signal independently of complex membership. A pulse followed by a chase does not make the covalent label disappear when the partner leaves.

Structural methods distinguish alternative interpretations of these measurements. cryo-electron microscopy can assign ordered subunits, estimate occupancy of resolved features, and separate some compositionally different particle classes. Flexible or small subunits may remain invisible despite being present. X-ray crystallography resolves stable interfaces but selects material that crystallizes. Förster resonance energy transfer between appropriately positioned labels tests nanometre-scale proximity in intact biological cells; single-particle tracking and fluorescence correlation spectroscopy can test comobility and exchange. Label placement, spectral cross-talk and accidental colocalization require controls. None of these techniques by itself reliably inventories every component.

The computational analysis should preserve these distinctions. Construct a protein interaction network with separate edge types for copurification, cross-linking and proximity labeling. Cluster reproducibly supported associations to propose modules, distinguish a stable core from variable accessory components, and integrate localization and measured protein abundance. Models such as AlphaFold 3 can propose interfaces for experimentally supported candidate components, but a confident predicted geometry does not demonstrate that an interaction occurs in the tested condition.^[ref] Test interfaces by site-directed mutagenesis, confirming normal protein folding, expression and localization before interpreting a lost interaction. Evaluate a proposed assembly against independently held-out cross-links or other measurements to reduce circular validation.

For perturbations, use vehicle controls, several doses and early-to-late sampling; randomize preparation and instrument order. Quantify input abundance alongside bait-normalized partner recovery. An illustrative relative recruitment statistic for partner $i$ at time $t$ iswhere $I^{\mathrm{IP}}$ is background-corrected recovered intensity, $b$ is the bait and $A_i$ is input abundance. This is an operational comparison under matched extraction and measurement response, not an absolute occupancy or dissociation constant. A doubled recovered partner signal with doubled input abundance and unchanged bait recovery gives $R_i=1$, illustrating why raw enrichment alone would mislead. Values near the detection limit need uncertainty bounds rather than unstable ratios.

A drug-induced loss of several core components could mean disassembly, degradation, changed localization or poor recovery. Distinguish them with input proteomics, microscopy and native fractionation, then test reversibility after washout and rescue by a drug-resistant target when feasible. For stress, monitor viability and extraction-resistant material; for disease-associated mutations, compare otherwise matched genetic backgrounds and rescue with the normal allele. post-translational modifications may recruit an accessory partner without changing the core. hydrogen-deuterium exchange mass spectrometry can then test interface exposure, but its altered exchange reports accessibility and structural dynamics rather than a new subunit by itself. A convincing remodeling claim is a reproducible change in assembly membership or occupancy, separated from changes in abundance, localization and assay recovery, and connected to a functional consequence.

The unliganded and peptide-bound preparations elute at almost the same volume, near 14 ml. They therefore have similar effective hydrodynamic sizes in this separation. A conformational change can occur without a large change in that measurement. The GFP–peptide-containing complex elutes earlier, near 10.5–11 ml, consistent with a larger particle; the later peak is consistent with excess unbound GFP–peptide.

The experiment supports ligand association but does not alone determine subunit number. Size-exclusion chromatography separates by access to pores, which depends on size and shape rather than mass alone. The similar peptide-free and peptide-bound elution volumes therefore do not establish identical conformations or exact molecular masses.

The main particles are approximately 120 kDa in both conditions. With 30 kDa per protein subunit, this supports a tetramer:The small peptide contribution is not clearly resolved as a separate mass increase at this scale. Together with the microscopy, the results support a conformational change of an existing tetramer, rather than a large change in oligomer number. Mass photometry reports the scattering-derived mass distribution of detected particles; it does not by itself identify which conformation a particle adopts or count small bound ligands precisely.

Ion-channel deactivation and ion-channel inactivation are different. Ion-channel deactivation closes an activation gate when the voltage returns toward rest. Ion-channel inactivation makes a channel unavailable even while depolarization remains favorable for activation. A minimal kinetic picture is a closed state, an open state and an unavailable state, with recovery required before reopening. This helps terminate inward electric current and produces a neuronal refractory period.

In rapid voltage-gated potassium channel N-type inactivation, a cytoplasmic terminal segment, sometimes supplied by an auxiliary subunit, blocks the open inner pore. The classic ball-and-chain inactivation picture is supported by loss of rapid ion-channel inactivation after removing the relevant terminal segment and restoration by an appropriate soluble peptide. This links a mobile structural element to open-pore blockade; it does not imply that all potassium channels use that mechanism.^[ref]

Slower C-type inactivation involves rearrangement near the selectivity filter and external pore. Dependence on pore structure, ion occupancy and extracellular ions distinguishes it from a simple cytoplasmic plugging particle. Different channels can combine several unavailable states, so a single recovery time constant need not describe every trace.

Fast ion-channel inactivation in canonical animal voltage-gated sodium channels involves the intracellular linker between domains III and IV, including its hydrophobic IFM motif, and is coupled to domain-IV voltage-sensor activation. The modern structural interpretation is an allosteric latch acting on the gate, rather than a universal literal particle sitting in the ion pathway. The older hinged-lid analogy is useful only with that qualification.^[ref]

Functionally, a voltage clamp trace shows electric current declining during a maintained step; a second test pulse measures recovery of availability. Holding-potential dependence separates an altered fraction of available channels from a mere change in maximal open electrical conductance. Persistent electric current after defective ion-channel inactivation, or delayed recovery that reduces subsequent responses, illustrates why both entry into and exit from unavailable states matter for excitability. A decaying macroscopic electric current alone does not uniquely identify the molecular mechanism.

In spectrin unfolding by force spectroscopy, the cantilever measures tension through its calibrated deflection, while displacement of the pulling point increases the separation of the protein attachments. The protein extension is obtained after allowing for cantilever compliance and any linker extension; it is not simply the commanded displacement.

A folded spectrin repeat stores much of its backbone in a compact domain. Between unfolding events, the already released chain is stretched: increasingly straight conformations have fewer accessible configurations, and the resisting entropic force rises nonlinearly. A peak is reached when a still-folded domain crosses an unfolding barrier on the timescale of the imposed loading. Its released backbone increases the available contour length abruptly. At nearly the same end-to-end distance the fractional extension $x/L$ is then smaller, so tension drops. Pulling resumes on the next, longer-chain elastic branch. Repeated release of domains produces the saw-tooth sequence.

The record is therefore evidence for sequential mechanical unfolding of modular structure, not repeated stretching of a fixed-length rod. For the nominal eight-domain construct, successive branches correspond to increasing numbers of unfolded repeats. The order and rupture forces can fluctuate because barrier crossing is thermally activated and depends on loading rate, structural heterogeneity and pulling geometry; equivalent repeats need not rupture at identical force.

The horizontal separation between worm-like-chain fits at the same force estimates the added contour length, whereas the vertical force drop at one extension reflects redistribution of tension. These are distinct measurements. A repeat increment near the specified $31.7\mathrm{nm}$ is consistent with repeated similar structural units. The gain is a net release relative to the folded span and attachment geometry; $31.7/106\mathrm{nm}$ is not automatically the universal contour length of a peptide residue.

During unloading, relaxation and possible refolding can restore compact domains. Hysteresis would indicate dissipative or kinetically delayed processes. Neither the peak force alone nor an arbitrary saw-tooth area directly equals an equilibrium unfolding free energy: one must separate chain elasticity, cantilever storage, irreversible loss and pulling-rate effects. The worm-like-chain branches describe released-chain elasticity, not the molecular transition state responsible for a rupture peak.